Blood biomarker changes in response to low-dose oral ketamine treatment in adults with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)

This secondary analysis across two trials (n=35) examined blood biomarkers and psychological changes in adults with major depressive disorder, with or without post-traumatic stress disorder, after low-dose oral ketamine treatment. Both groups showed improvements in several measures, including depression or PTSD symptoms, anxiety, stress and well-being, alongside decreases in blood BDNF and VEGF-A, with no detectable difference between diagnoses.